Misoprostol dose selection in a controlled-release vaginal insert for induction of labor in nulliparous women

被引:17
作者
Castañeda, CS
Puente, JCI
Ochoa, RAL
Plasse, TF
Powers, BL
Rayburn, WF
机构
[1] Cytokine PharmaSci Inc, King Of Prussia, PA 19406 USA
[2] Clin Materno Infante, Toluca, Mexico
[3] Hosp Ginelo Obstet, Mexico City, DF, Mexico
[4] Hosp Reg 1 Octubre, Mexico City, DF, Mexico
[5] Univ New Mexico, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA
关键词
induction of labor; misoprostol; controlled-release; vaginal insert; cervical ripening;
D O I
10.1016/j.ajog.2005.06.072
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The purpose of this study was to identify the maximum tolerable dose and to determine the efficacy of different misoprostol dose reservoirs in an intravaginal controlled-release hydrogel polymer. Study design: Nulliparous women at >= 37 weeks' gestation requiring cervical ripening and induction of labor were treated with misoprostol in a controlled-release, retrievable hydrogel polymer vaginal insert. Sequential cohorts of 6 patients were to be treated with escalating dose reservoirs of 25, 50, 100, 200, and 300 mu g. The insert was to be removed upon onset of active labor, at 24 hours, or earlier if treatment-related adverse events occurred. The safety end point was determination of the maximum tolerable dose (MTD) based on occurrence of hyperstimulation syndrome. Our primary efficacy end point was time to vaginal delivery. Results: Increasing reservoir doses of misoprostol up to 100 mu g produced more rapid increases in modified Bishop scores, less need for oxytocin, and a shorter time to vaginal delivery. Doses above 100 mu g did not further enhance cervical ripening or shorten time to vaginal delivery. The median time to vaginal delivery was 14.2 hours using the 100 mu g dose. Uterine hyperstimulation and adverse fetal heart rate effects occurred with the 200 and 300 mu g inserts. Conclusion: The 100 mu g vaginal insert resulted in successful cervical ripening and rapid vaginal delivery with an acceptable safety profile for future randomized clinical trials. (C) 2005 Mosby, Inc. All rights reserved.
引用
收藏
页码:1071 / 1075
页数:5
相关论文
共 11 条
[1]  
*ACOG, 1995, ACOG TECHN B
[2]  
*ACOG, 2000, NEW US FDA LAB CYT M
[3]  
*ACOG, 2003, DYST AUGM LAB ACOG P
[4]  
CALDER AA, 1974, BJOG, V82, P39
[5]  
HOFMEYR GJ, 2003, COCHRANE LIB
[6]  
Parer JT, 1997, AM J OBSTET GYNECOL, V177, P1385
[7]   Rising rates of labor induction: Present concerns and future strategies [J].
Rayburn, WF ;
Zhang, J .
OBSTETRICS AND GYNECOLOGY, 2002, 100 (01) :164-167
[8]   Misoprostol for cervical ripening and labor induction: A systematic review of the literature [J].
Sanchez-Ramos, L ;
Kaunitz, AM .
CLINICAL OBSTETRICS AND GYNECOLOGY, 2000, 43 (03) :475-488
[9]   Dose variation that is associated with approximated one-quarter tablet doses of misoprostol [J].
Williams, MC ;
Tsibris, JCM ;
Davis, G ;
Baiano, J ;
O'Brien, WF .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (03) :615-619
[10]   Labor induction with misoprostol [J].
Wing, DA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (02) :339-345